These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9531305

  • 21. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX, Chen BG, Plautz GE.
    J Immunol; 2002 Sep 15; 169(6):3314-20. PubMed ID: 12218152
    [Abstract] [Full Text] [Related]

  • 22. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY, Chou T, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):295-304. PubMed ID: 2953816
    [Abstract] [Full Text] [Related]

  • 23. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 24. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY, Chou T, Sakai K.
    J Immunol; 1989 Jul 15; 143(2):740-8. PubMed ID: 2738408
    [Abstract] [Full Text] [Related]

  • 25. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
    Peng L, Kjaergäard J, Plautz GE, Awad M, Drazba JA, Shu S, Cohen PA.
    J Immunol; 2002 Nov 01; 169(9):4811-21. PubMed ID: 12391191
    [Abstract] [Full Text] [Related]

  • 26. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD.
    Cancer Res; 1993 Feb 15; 53(4):833-9. PubMed ID: 8428364
    [Abstract] [Full Text] [Related]

  • 27. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, Czerniecki BJ, Shu S.
    Crit Rev Immunol; 2001 Feb 15; 21(1-3):215-48. PubMed ID: 11642606
    [Abstract] [Full Text] [Related]

  • 28. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes.
    Lynch DH, Namen AE, Miller RE.
    Eur J Immunol; 1991 Dec 15; 21(12):2977-85. PubMed ID: 1684156
    [Abstract] [Full Text] [Related]

  • 29. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K, Chang AE, Shu SY.
    Cancer Res; 1990 Jul 15; 50(14):4371-6. PubMed ID: 2114215
    [Abstract] [Full Text] [Related]

  • 30. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ.
    J Immunol; 1998 Jan 01; 160(1):334-44. PubMed ID: 9551989
    [Abstract] [Full Text] [Related]

  • 31. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S, Chou T, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3891-8. PubMed ID: 3486223
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S, Rosenberg SA.
    J Immunol; 1985 Oct 15; 135(4):2895-903. PubMed ID: 2411817
    [Abstract] [Full Text] [Related]

  • 34. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH.
    Cancer Res; 2000 May 01; 60(9):2449-57. PubMed ID: 10811123
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL.
    Gynecol Oncol; 2001 Jun 01; 81(3):424-32. PubMed ID: 11371133
    [Abstract] [Full Text] [Related]

  • 37. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD.
    Cancer Res; 1992 Feb 01; 52(3):548-53. PubMed ID: 1732041
    [Abstract] [Full Text] [Related]

  • 38. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells.
    Matesic D, Valujskikh A, Pearlman E, Higgins AW, Gilliam AC, Heeger PS.
    J Immunol; 1998 Nov 15; 161(10):5236-44. PubMed ID: 9820495
    [Abstract] [Full Text] [Related]

  • 39. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S.
    Cancer Res; 2001 Mar 01; 61(5):2031-7. PubMed ID: 11280763
    [Abstract] [Full Text] [Related]

  • 40. CDR3 spectratyping identifies clonal expansion within T-cell subpopulations that demonstrate therapeutic antitumor activity.
    Kim JA, Rao P, Graor H, Rothchild K, O'keefe C, Maciejewski JP.
    Surgery; 2004 Aug 01; 136(2):295-302. PubMed ID: 15300194
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.